A Registry to Assess Long-Term Safety of Patients With B-Lymphocyte Malignancies Treated With Tisagenlecleucel in South Korea
Latest Information Update: 24 Jan 2025
Price :
$35 *
At a glance
- Drugs Tisagenlecleucel (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 24 Jan 2025 New trial record